Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
|Videos|November 2, 2018
Rationale for Using TAS-102 in Patients With Gastric Cancer
Author(s)Hendrik-Tobias Arkenau, MD, PhD
Hendrik-Tobias Arkenau, MD, PhD, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.
Advertisement
Hendrik-Tobias Arkenau, MD, PhD, executive medical director, executive medical director for Sarah Cannon Research Institute UK, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.
Arkenau emphasizes that gastric cancers are one of the most common cancers worldwide and are related to both the third and fifth most common cancers. TAS-102 has shown good clinical evidence in patients with colorectal cancer and patients with gastric or gastroesophageal cancer.
Advertisement
Related to this article
Short-course neoadjuvant botensilimab plus balstilimab drives deep responses in resectable pMMR and dMMR colon cancer, with ctDNA clearance and no recurrences.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.
Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
The GOBLET trial showed durability in patients with previously treated squamous cell anal carcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5